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PAD is a widespread cardiovascular disease, in 2010 an estimated 40.5 million people lived 
with PAD in the European region (1), and patient numbers are increasing worldwide (2). 
Some patients with PAD experience chronic pain, have a reduced walking distance or may 
become dependent on other people to handle everyday life (3). Additionally, patients with 
PAD have a high risk for cardiovascular events such as heart attack or stroke, and for death 
from cardiovascular causes. Treatment of PAD therefore includes physiotherapy, lifestyle 
interventions, treatment with drugs i.e. pharmacological treatment, and (repeated) 
invasive treatment, this can include surgery or minimally-invasive interventions to 
improve the blood flow to the affected extremities (2, 4, 5). New pharmacological 
treatment options and invasive treatment techniques and materials are becoming 
available, potentially reducing the burden of the disease to the patient, but also 
potentially increasing treatment costs and economic burden of PAD (6-17). In this context, 
the evaluation of costs, clinical outcomes, and the value for money i.e. cost-effectiveness 
of such new PAD treatments becomes increasingly relevant. 
The objective of the thesis was to 1) investigate current PAD treatment patterns, 2) 
measure the quality of life of patients with PAD and to estimate the costs of PAD 
treatment, and 3) to assess the cost-effectiveness of new pharmacologic treatment 
strategies for PAD. 
The first sub-objective aimed to identify groups of PAD patients with different treatment 
needs according to their cardiovascular risk and their probability of undergoing invasive 
PAD treatment, i.e. revascularization probability. Purpose of the identification of these 
groups was to explore if patient characteristics available at PAD diagnosis could be used to 
anticipate these treatment needs. Chapter 2, addressing this first sub-objective, described 
the analysis of characteristics of 274 patients newly diagnosed with PAD, and their 
treatment following diagnosis. Groups of PAD patients who developed different treatment 
needs were identified, and the relationship between group membership and patient 
characteristics were explored. This relationship was analysed in two ways: 1) Venn 
diagrams identified combinations of characteristics that were related to increased 
cardiovascular risk and reduced revascularization eligibility, 2) a regression analysis was 
used to analyse predictors of increased revascularization probability. On the one hand, the 
Venn diagrams identified four combinations of characteristics that characterized patients 
with reduced revascularization eligibility due their cardiovascular profile. These 
combinations were (a) insulin-dependent diabetes and impaired renal function, (b) History 
of MI and obesity, (c) insulin-dependent diabetes and history of MI, and (4) Age > 75, 
obesity and insulin-dependent diabetes. Within the patient cohort analysed, 5.1% of 
patients had such a combination of characteristics that identified them as likely ineligible 
for revascularization and thus dependent on stringent pharmacological cardiovascular 
prevention. Treatment for such patients who are at increased cardiovascular risk and need 
for extra measures to prevent PAD progression as well as cardiovascular events may 
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benefit from intensified and individualised pharmacological treatment. On the other hand, 
the regression analysis showed a number of characteristics of patients who are at higher 
risk of undergoing invasive PAD treatment. These characteristics were younger age, lower 
physical functioning, and lower quality of life, as well as more severe Fontaine stages and 
worsening complaints. Identifying this group of patients who are more likely to need 
revascularization may help GPs treating PAD patients refer patients with such 
characteristics and signs of worsening of the disease to the vascular surgeon earlier. By 
involving the vascular surgeon earlier, the decision to switch from conservative to invasive 
treatment will not be delayed, which may benefit the patient. The findings of the study 
presented in Chapter 2 may help develop guidance for PAD treatment in the primary care 
setting, where additional information on a patient’s future treatment needs may help 
doctors determine the best treatment approach for newly diagnosed PAD patients. 
 
The second sub-objective of the thesis was to measure the quality of life of patients with 
PAD and to estimate the costs of PAD treatment in the first two years after diagnosis. 
Chapter 3 describes the quality of life of patients with new PAD, and the effect of invasive 
and conservative treatment using two different measurement instruments, the SF-6D and 
EQ-5D. Quality of life data from 229 patients with newly diagnosed PAD was analysed. The 
data had been collected during a time period of two years starting from diagnosis of PAD. 
The analyses compared the effect of non-invasive, i.e. conservative vs. invasive PAD 
treatment one and two years after diagnosis. To enable a comparison between the 
conservative and invasive treatment groups, differences in characteristics of the groups 
were adjusted for using a matching technique (propensity score matching). The effects of 
invasive treatment and conservative treatment were estimated, patient characteristics 
that influenced the extend of the treatment effect were identified. At year one, 30.6% of 
patients had received invasive treatment, 7.4% received invasive treatment during the 
second year. The EQ-5D instrument indicated that QoL after invasive treatment was 
higher, and more patients reported ‘no problems’ with pain/discomfort, mobility and 
usual activities after invasive treatment. The SF-6D instrument indicated that physical 
functioning, role limitations physical and pain were improved after invasive treatment. 
Both treatments showed a positive effect on quality of life measured by the EQ-5D, the SF-
6D measured a small negative effect of conservative treatment. The comparison between 
patients who received invasive treatment and patients who received conservative 
treatment showed that the effect of treatment on quality of life was dependent on the 
quality of life at PAD diagnosis. Patients with lower quality of life and patients who 
experienced rest-pain at diagnosis gained more quality of life with PAD treatment. The 
difference in effect between conservative and invasive treatment was not statistically 
significant. The effect of invasive treatment was numerically larger. The analysis 
highlighted that both conservative and invasive treatment improved the quality of life of 
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patients with PAD. The EQ-5D was more sensitive to changes in quality of life and 
differences between patient groups. 
In Chapter 4 we quantified the costs of PAD and PAD treatment by estimating the costs of 
mild PAD and moderate PAD, of peripheral revascularization i.e. invasive treatment and 
the cost of illness of PAD in the Netherlands overall (Chapter 4). Based on a bottom-up 
approach, using data from a smaller cohort of patients with PAD to estimate the costs 
within a much larger population, we estimated the cost of illness of PAD of the entire 
population of PAD patients in the Netherlands. Resource use and costs of 245 new Dutch 
PAD patients over a period of two years starting from PAD diagnosis were analysed. The 
impact of patient characteristics on PAD costs was explored using generalized linear 
regression. The costs of all new and all prevalent cases of PAD in the Netherlands were 
estimated. Over the first two years of treatment, 64.5% of patients exclusively received 
conservative treatment and 35.5% received invasive treatment at least once. Patients 
reported going to the GP and to the physiotherapist most often. The costs of PAD 
treatment were highest 3 months after diagnosis, and lowest 24 months after diagnosis. 
This was largely driven by the costs of invasive treatment. During the three months before 
PAD diagnosis, the majority of costs were related to specialist care. The total cost over the 
27 months period (3 months before hospital-based diagnosis up to the 24 months after 
diagnosis) were €7,504 per patient; €4,265 (BCI €3,836 – €4,796) in the first year and 
€2,789 (BCI €2,307 – €3,324) in the second year. Costs were higher in patients with a high 
BMI and patients undergoing (repeated) invasive treatment, and lower in patients using 
cholesterol-lowering drugs and in patients with a high quality of life at diagnosis. The 
annual healthcare costs of patients with mild PAD and moderate PAD were €2,031 and 
€2,318, respectively. The costs of a revascularization were €4,422. Considering there are 
26,489 new PAD patients in the Netherlands per year, the costs of new PAD are estimated 
to be €113.1 million in the first year and €72.4 million in the second year of PAD treatment 
(18). The annual costs of 613,000 prevalent PAD cases amount to €1.26 billion (19). This is 
comparable to the estimated €1.3 billion spent on the treatment of other cardiovascular 
disease such as ischemic heart disease in the Netherlands according to the European 
cardiovascular disease statistics (19).  
The third and last sub-objective was to assess the cost-effectiveness of a new 
pharmacological treatment, rivaroxaban plus aspirin, for cardiovascular disease including 
PAD. In Chapter 5 we used a health-economic model to assess the costs and clinical 
outcomes of dual pathway inhibition (DPI) with 2.5mg rivaroxaban twice daily plus 100mg 
aspirin compared to aspirin alone for the prevention of heart attacks, strokes and death 
from cardiovascular disease in patients with coronary artery disease (CAD) or/and PAD. In 
patients with PAD, treatment with DPI and with aspirin were also compared to treatment 
with clopidogrel. A state transition model was developed, i.e. a model that simulated how 
a hypothetical cohort of patients treated with either of the treatment options would over 
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time transition through a set of health states representing the different health conditions 
the patients could be in. In this case, these health conditions reflected stable disease, 
cardiovascular events as heart attack, or ischemic and haemorrhagic stroke, worsening of 
PAD, bleeding events, and death. To estimate the health outcomes and costs of each 
treatment option, costs and quality of life consequences were attached to each health 
state and summed up considering the amount of time patients would spend in each health 
state. Evidence from two clinical trials were used to model the effect of treatment with 
DPI, aspirin and clopidogrel. The model evaluated the treatments by estimating health 
outcomes and costs over a lifetime horizon. The results were standardized units of health 
gained, which was expressed in quality-adjusted life years (QALY), and costs. The cost per 
QALY was compared against the willingness-to-pay threshold per unit of health gained by 
the Dutch health authorities (€50,000 per QALY). This reflected the value for money 
provided by the treatments from a Dutch healthcare perspective. The analysis showed 
that in CAD patients and in PAD patients, DPI provided the best health outcomes (longer 
survival, higher number of QALYs) and the highest costs. The additional costs stemmed 
largely from higher drug costs. This resulted in a cost per QALY of €32,109 for the 
treatment of CAD, and of €26,381 for the treatment of PAD when comparing DPI to 
aspirin. Treatment with clopidogrel was less cost-effective than with DPI. The probability 
of DPI being cost-effective was 92% and 56% in CAD and PAD patients. The annual 
healthcare costs would increase by €38.7 million if DPI was implemented for the 
treatment of CAD and would increase by €29.0 million if DPI was implemented for the 
treatment of PAD. The relationship between costs and effects of treatment with DPI 
differed in some subgroups of CAD and PAD patients. The costs per QALY was lowest in 
PAD patients with additional diseases and in CAD patients younger than 65, this indicated 
that treatment would be most cost-effective in these patients. The costs per QALY were 
highest in PAD patients with carotid artery disease and in CAD patients older than 75, this 
indicated that treatment with DPI would be less cost-effective. Chapter 5 ended with a 
discussion of limitations of the study and of the evidence used, and how these impact the 
decision uncertainty. It was highlighted that unavailability of detailed trial data 
contributed considerable uncertainty as assumptions had to be made where data from 
clinical trials should ideally be used, but these were not made available. The level of 
evidence informing the effectiveness of clopidogrel was identified as another uncertainty, 
specifically regarding the cost-effectiveness of DPI for the treatment of patients with PAD.  
Chapter 6 continued by exploring the feasibility of a comprehensive uncertainty 
assessment of health economic models, using the model described in Chapter 5 as a case 
study. The aim was to parameterize all influential uncertainties and reflect them in the 
cost-effectiveness probability and risk associated with the adoption decision. The 
uncertainties applying to the model were identified and added to the probabilistic 
sensitivity analysis if possible. Parameter distributions were obtained by expert elicitation, 
and structural uncertainties were either parameterized or explored in scenario analyses 
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which were model averaged. The case study highlighted that a truly comprehensive 
uncertainty assessment could not be achieved, and several subjective judgments and 
decisions were necessary in the process of the uncertainty assessments, which potentially 
reduced the comprehensiveness and transparency of the approach. Expert elicitation 
regarding the value of parameters that were uncertain showed to be a useful tool in 
parameterizing previously unexplored uncertainties, and in reflecting them in the cost-
effectiveness results. Guidance regarding the use of applicable methodologies, such as the 
selection of uncertainties, the use of expert elicitation, the aggregation of elicited and 
existing data, the use of model averaging, and reporting the results in a comprehensive 
and transparent manner was missing and perceived as a barrier to the comprehensive 
uncertainty assessment. The use of existing tools such as TRUST for the assessment of 
uncertainties (20), and EXPLICIT for the elicitation of expert opinion (21) were perceived as 
facilitators. The study provided an example of how comprehensive uncertainty 
assessment can be conducted by utilizing existing tools and available sources of expert 
knowledge. It also underlined that the requirements for comprehensive uncertainty 
assessment need better definition by those potentially using it – decision makers in 
healthcare – and more attention regarding the development of guidance and instructions 
for the appropriate use of methodologies is needed. 
The last chapter (Chapter 7) of this dissertation summarizes the main findings and 
discusses implications on HTA methodology. Furthermore, implications on clinical and 
policy decisions making regarding care for PAD patients are outlined. Based on the 
research conducted, areas that require further research are described. Regarding the field 
of HTA, these include the handling of missing cost data, the systematic identification and 
parameterization of uncertainties relating to health economic models and the use of 
expert elicitation tools in HTA. Regarding the clinical and policy aspects of care for PAD 
patients, these include the further development of prediction tools for the anticipation of 
future treatment needs, the use of intensified conservative treatment and the role of non-
clinical characteristics in the treatment pathway of PAD patients.  
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